Public relations company Padilla announced on Thursday that three in five US employees working without a COVID-19 vaccination policy expect their companies to create one and would not feel comfortable returning to work unless at least 50% of all employees are vaccinated.
This survey is based a new study commissioned by Padilla and conducted by its research division, SMS Research Advisors. SMS Research Advisors surveyed 1,026 people employed in the workforce of varying ages, positions/levels and industries in January 2021, with 8.4% of survey respondents working in health care. About 85% of employees supported the approach of COVID-19 vaccine policy.
Almost half of employees working for companies with 1,000 or fewer co-workers, want 75% or more of their co-workers vaccinated before they return to the workplace. In general, organizations are not requiring their employees to receive a COVID-19 vaccine, added Padilla.
The most common opposition to a mandatory workplace vaccination policy comes from employees who want to receive a vaccine, but do not think their employer should require it and those who oppose the vaccine altogether and do not want their employer to require it. The vaccinations should be mandatory for any job that requires human-to-human interaction, concluded Padilla.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients